Home Newsfeeds Mizuho Maintains Neutral on Xylem, Raises Price Target to $88

Mizuho Maintains Neutral on Xylem, Raises Price Target to $88

Mizuho analyst Brett Linzey maintains Xylem (NYSE:XYL) with a Neutral and raises the price target from $80 to $88.

byBenzinga Newsdesk

August 3, 2022

1 minute read

Mizuho analyst Brett Linzey maintains Xylem (NYSE:XYL) with a Neutral and raises the price target from $80 to $88.

Movers
News

Why Ionis Pharmaceuticals Stock Popped Today

By Ryan Gustafson

September 26, 3:49 PM

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading higher Tuesday after the company announced the Phase 3 Balance study of olezarsen met the primary endpoint with a statistically significant reduction in

IONS

News

U.S. Treasury’s Yellen Says Treasury Working With Regulators On Reforms To Improve Treasury Debt Market’s Ability To ‘absorb Shocks And Disruptions, Rather Than To Amplify Them’; Treasury Market Now Reflects Greater Uncertainty About Economic Outlook,…

By Benzinga Newsdesk

October 24, 11:06 AM

- Reuters

SPY

Back-To-Back Three Japanese Approvals For AstraZeneca’s Rare Disease Treatments

By Vandana Singh

August 25, 8:50 AM

The Japan regulatory authority has approved AstraZeneca Plc (NASDAQ:AZN) and Merck Co Inc’s (NYSE:MRK) Lynparza (olaparib) for the adjuvant treatment of patients with…

AZN

iQIYI Q4 Adj EPS $0.14 Beats $0.02 Estimate, Sales $1.10B Beat $1.09B Estimate

By Benzinga Newsdesk

February 22, 5:03 AM

iQIYI (NASDAQ:IQ) reported adjusted quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.02 by 600 percent. This is a 140 percent increase over losses of $(0.35) per share from the same

Mizuho Maintains Neutral on Xylem, Raises Price Target to $88

Related Posts

Why Ionis Pharmaceuticals Stock Popped Today

U.S. Treasury’s Yellen Says Treasury Working With Regulators On Reforms To Improve Treasury Debt Market’s Ability To ‘absorb Shocks And Disruptions, Rather Than To Amplify Them’; Treasury Market Now Reflects Greater Uncertainty About Economic Outlook,…

Back-To-Back Three Japanese Approvals For AstraZeneca’s Rare Disease Treatments

iQIYI Q4 Adj EPS $0.14 Beats $0.02 Estimate, Sales $1.10B Beat $1.09B Estimate